Dementia Risk in Psoriasis Patients Treated with Biologics: A Propensity Score-matched Population-based Cohort Study
DOI:
https://doi.org/10.2340/actadv.v105.43243Keywords:
psoriasis, dementia, biologic therapy, anti-interleukin 17, interleukin-23, anti-tumor necrosis factor-α antibodyAbstract
Translational research and animal models suggest that psoriasis treatments may have neuroprotective effects and reduce dementia risk. This study evaluates the association between biologic therapies for psoriasis and dementia incidence. A retrospective cohort included patients aged 65 or older with psoriasis, divided into 2 groups: those receiving biologic therapy following systemic treatment and those on systemic treatment alone. Patients with prior dementia were excluded. Dementia diagnosis was assessed at least 12 months after biologic initiation. Propensity score matching yielded 1,766 patients (883 per group). Biologic therapy was associated with a 53% reduced dementia risk (hazard ratio 0.47, 95% confidence interval 0.323–0.699), supported by a multivariate Cox model (adjusted hazard ratio 0.52, 95% confidence interval 0.392–0.699). These findings suggest that biologic therapies targeting tumour necrosis factor-alpha, interleukin-17, and interleukin-23 may reduce the risk of dementia, even after adjusting for age and other confounders.
Downloads
References
Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol 2017; 31: 205–212.
https://doi.org/10.1111/jdv.13854 DOI: https://doi.org/10.1111/jdv.13854
Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol 2014; 70: 512–516.
https://doi.org/10.1016/j.jaad.2013.11.013 DOI: https://doi.org/10.1016/j.jaad.2013.11.013
Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 2020; 323: 1945–1960.
https://doi.org/10.1001/jama.2020.4006 DOI: https://doi.org/10.1001/jama.2020.4006
Nestle FO, Kaplan DH, Barker J. Mechanisms of disease: psoriasis. N Engl J Med 2009; 361: 496–509.
https://doi.org/10.1056/NEJMra0804595 DOI: https://doi.org/10.1056/NEJMra0804595
Ferrari E, Cravello L, Bonacina M, Salmoiraghi F, Magri F. Stress and dementia. In: Steckler T, Kalin NH, Reul JMHM, eds. Techniques in the behavioral and neural sciences: Part 2: Stress: integrative and clinical aspects. Vol 15. Amsterdam: Elsevier, 2005: p. 357–370.https://doi.org/10.1016/S0921-0709(05)80064-1 DOI: https://doi.org/10.1016/S0921-0709(05)80064-1
Van der Flier WM, Scheltens P. Epidemiology and risk factors of dementia. J Neurol Neurosurg Psychiatry 2005; 76: v2–v7.
https://doi.org/10.1136/jnnp.2005.082867 DOI: https://doi.org/10.1136/jnnp.2005.082867
Hugo J, Ganguli M. Dementia and cognitive impairment: epidemiology, diagnosis, and treatment. Clin Geriatr Med 2014; 30: 421–442.
https://doi.org/10.1016/j.cger.2014.04.001 DOI: https://doi.org/10.1016/j.cger.2014.04.001
Rabinovici GD. Late-onset Alzheimer disease. Continuum (Minneap Minn) 2019; 25: 14–33.
https://doi.org/10.1212/CON.0000000000000700 DOI: https://doi.org/10.1212/CON.0000000000000700
Wu CY, Hu HY, Chou YJ, LI CP, Chang YT. Psoriasis is not a risk factor for dementia: a 12-year nationwide population-based cohort study. Arch Dermatol Res 2020; 312: 657–664.
https://doi.org/10.1007/s00403-020-02057-2 DOI: https://doi.org/10.1007/s00403-020-02057-2
Kridin K, Linder D, Shalom G, Piaserico S, Babaev M, Freud T, Comaneshter D, et al. Psoriasis and dementia: a cross-sectional study of 121801 patients. Acta Derm Venereol 2020; 100: 5844.
https://doi.org/10.2340/00015555-3595 DOI: https://doi.org/10.2340/00015555-3595
Pezzolo E, Mutlu U, Vernooij M, Dowlatshahi W, Gisondi EA, Girolomoni P, et al. Psoriasis is not associated with cognition, brain imaging markers, and risk for dementia: the Rotterdam Study. J Am Acad Dermatol 2021; 85: 671–680.
https://doi.org/10.1016/j.jaad.2018.07.046 DOI: https://doi.org/10.1016/j.jaad.2018.07.046
Kim M, Park HE, Lee SH, Han K, Lee JH. Increased risk of Alzheimer’s disease in patients with psoriasis: a nationwide population-based cohort study. Sci Rep 2020; 10: 1–7.
https://doi.org/10.1038/s41598-020-63550-2 DOI: https://doi.org/10.1038/s41598-020-63550-2
Yen H, Yen H, Chi CC. Is psoriasis associated with dementia or cognitive impairment? A critically appraised topic. Br J Dermatol 2021; 184: 34–42.
https://doi.org/10.1111/bjd.19025 DOI: https://doi.org/10.1111/bjd.19025
Huang KL, Yeh CC, Wu SI, Huang KY, Yang YH, Kuo, TY, et al. Risk of dementia among individuals with psoriasis: a nationwide population-based cohort study in Taiwan. J Clin Psychiatry 2019; 80: 15854.
https://doi.org/10.4088/JCP.18m12462 DOI: https://doi.org/10.4088/JCP.18m12462
Lam M, Khorvash R, Drucker AM. Association between psoriasis and risk of dementia: a systematic review and meta-analysis. J Am Acad Dermatol 2021; 84: 790–792.
https://doi.org/10.1016/j.jaad.2020.05.091 DOI: https://doi.org/10.1016/j.jaad.2020.05.091
Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 2015; 16: 358–372.
https://doi.org/10.1038/nrn3880 DOI: https://doi.org/10.1038/nrn3880
Milovanovic J, Arsenijevic A, Stojanovic B, Kanjevac T, Arsenijevic, D, Radosavljevic G, et al. Interleukin-17 in chronic inflammatory neurological diseases. Front Immunol 2020; 11: 947.
https://doi.org/10.3389/fimmu.2020.00947 DOI: https://doi.org/10.3389/fimmu.2020.00947
Chen JM, Jiang GX, Li QW, Zhou ZM, Cheng Q. Increased serum levels of interleukin-18, -23, and -17 in Chinese patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 2014; 38: 321–329.
https://doi.org/10.1159/000360606 DOI: https://doi.org/10.1159/000360606
Vellecco V, Saviano A, Raucci F, Casillo GM, Mansour AA, Panza E, et al. Interleukin-17 triggers systemic inflammation, peripheral vascular dysfunction, and related prothrombotic state in a mouse model of Alzheimer’s disease. Pharmacol Res 2023; 187: 106595.
https://doi.org/10.1016/j.phrs.2022.106595 DOI: https://doi.org/10.1016/j.phrs.2022.106595
Torres-Acosta N, O’Keefe JH, O’Keefe EL, Isaacson R, Small G. Therapeutic potential of TNF-α inhibition for Alzheimer’s disease prevention. J Alzheimers Dis 2020; 78: 619–626.
https://doi.org/10.3233/JAD-200711 DOI: https://doi.org/10.3233/JAD-200711
Zheng Y, Zhang X, Zhang R, Wang Z, Gan J, Gao Q, et al. Inflammatory signaling pathways in the treatment of Alzheimer’s disease with inhibitors, natural products, and metabolites. Int J Mol Med 2023; 52: 1–42.
https://doi.org/10.3892/ijmm.2023.5314 DOI: https://doi.org/10.3892/ijmm.2023.5314
Calsolaro V, Edison P. Neuroinflammation in Alzheimer’s disease: current evidence and future directions. Alzheimers Dement 2016; 12: 719–732.
https://doi.org/10.1016/j.jalz.2016.02.010 DOI: https://doi.org/10.1016/j.jalz.2016.02.010
Mudrenko I, Chyniak O. Association between IL-17, IL-23 with neurocognitive scales in patients with Alzheimer’s disease. Eur Psychiatry 2021; 64: S718–S719.
https://doi.org/10.1192/j.eurpsy.2021.1903 DOI: https://doi.org/10.1192/j.eurpsy.2021.1903
Zhou M, Xu R, Kaelber DC, Gurney ME. Tumor necrosis factor blocking agents are associated with lower risk for Alzheimer’s disease in patients with rheumatoid arthritis and psoriasis. PLoS One 2020; 15: e0229819.
https://doi.org/10.1371/journal.pone.0229819 DOI: https://doi.org/10.1371/journal.pone.0229819
Cristiano C, Volpicelli F, Lippiello P, Buono B, Raucci F, Piccolo M, et al. Neutralization of IL-17 rescues amyloid-β-induced neuroinflammation and memory impairment. Br J Pharmacol 2019; 176: 3544–3557.
https://doi.org/10.1111/bph.14586 DOI: https://doi.org/10.1111/bph.14586
Chen JM, Li QW, Jiang GX, Liu JS, Cheng Q. IL-18 induced IL-23/IL-17 expression impairs Aβ clearance in cultured THP-1 and BV2 cells. Cytokine 2019; 119: 113–118.
https://doi.org/10.1016/j.cyto.2019.03.003 DOI: https://doi.org/10.1016/j.cyto.2019.03.003
Xie W, Hou Y, Xiao S, Zhang X, Zhang Z. Association between disease-modifying antirheumatic drugs for rheumatoid arthritis and risk of incident dementia: a systematic review with meta-analysis. RMD Open 2024; 10: e004016.
https://doi.org/10.1136/rmdopen-2023-004016 DOI: https://doi.org/10.1136/rmdopen-2023-004016
National Insurance Institute of Israel. Health insurance in Israel 2017 survey. [Accessed 25 Aug 2023] Available from: https://www.btl.gov.il/Publications/survey/Pages/seker_303.aspx.
Central Bureau of Statistics. Characterization and ranking of different geographical units in Israel. Available from: https://www.cbs.gov.il. Accessed Jan 2024.
Taquet M, Dercon Q, Todd JA, Harrison PJ. The recombinant shingles vaccine is associated with lower risk of dementia. Nat Med 2024; 30: 2777–2781.
https://doi.org/10.1038/s41591-024-03201-5 DOI: https://doi.org/10.1038/s41591-024-03201-5
Reuben DB, Kremen S, Maust DT. Dementia prevention and treatment: a narrative review. JAMA Intern Med 2024; 184: 563–572.
https://doi.org/10.1001/jamainternmed.2023.8522 DOI: https://doi.org/10.1001/jamainternmed.2023.8522
Chou RC, Kane M, Ghimire S, Gautam, S, Gui J. Treatment for rheumatoid arthritis and risk of Alzheimer’s disease: a nested case-control analysis. CNS Drugs 2016; 30: 1111–1120.
https://doi.org/10.1007/s40263-016-0374-z DOI: https://doi.org/10.1007/s40263-016-0374-z
Feldman SR, Zhao Y, Shi L, Tran MH, Lu J. Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis. Arthritis Care Res 2015; 67: 708–717.
https://doi.org/10.1002/acr.22492 DOI: https://doi.org/10.1002/acr.22492
Menter A, Korman NJ, Elmets CA, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826–850.
https://doi.org/10.1016/j.jaad.2008.02.039 DOI: https://doi.org/10.1016/j.jaad.2008.02.039
Kampe T, Dorko E, Rimárová K, Houžvičková A, Baloghová J, Baranová, Z, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. Cent Eur J Public Health 2022; 30: S05–S10.
https://doi.org/10.21101/cejph.a6806 DOI: https://doi.org/10.21101/cejph.a6806
Katamanin OM, Tan IJ, Barry J, Jafferany M. Role of inflammation and cytokine dysregulation in depression in patients with inflammatory skin conditions. Am J Clin Dermatol 2024; 25: 1–9.
https://doi.org/10.1007/s40257-024-00905-9 DOI: https://doi.org/10.1007/s40257-024-00905-9
Dou Y, You J, Wang J, Li X, Lin Y, Liu B, et al. IL-17A mediates depressive-like symptoms by inducing microglia activation in psoriasiform dermatitis mice. Immun Inflamm Dis 2024; 12: e70092.
https://doi.org/10.1002/iid3.70092 DOI: https://doi.org/10.1002/iid3.70092
Wang K, Fang Y, Zheng R, Zhao X, Wang S, Lu J, et al. Associations of socioeconomic status and healthy lifestyle with incident dementia and cognitive decline: two prospective cohort studies. EClinicalMedicine 2024; 76: 102831.
https://doi.org/10.1016/j.eclinm.2024.102831 DOI: https://doi.org/10.1016/j.eclinm.2024.102831
Kalaria R, Maestre G, Mahinrad S, Acosta DM, Akinyemi RO, Alladi S, et al. The 2022 symposium on dementia and brain aging in low- and middle-income countries. Alzheimers Dement 2024; 20: 4290–4314.
https://doi.org/10.1002/alz.13836 DOI: https://doi.org/10.1002/alz.13836
Shalom G, Zisman D, Bitterman H, Harman-Boehm I, Greenberg-Dotan S, Dreiher J, et al. Systemic therapy for psoriasis and the risk of herpes zoster: a 500000 person-year study. JAMA Dermatol 2015; 151: 533–538.
https://doi.org/10.1001/jamadermatol.2014.4956 DOI: https://doi.org/10.1001/jamadermatol.2014.4956
Additional Files
Published
How to Cite
License
Copyright (c) 2025 Jen A. Barak Levitt, Michael Ziv
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
